Cite
HARVARD Citation
Kaddu-Mulindwa, D. et al. (2022). KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. Lancet. 9 (2), pp. e133-e142. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Kaddu-Mulindwa, D. et al. (2022). KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. Lancet. 9 (2), pp. e133-e142. [Online].